TMCnet News
Research and Markets: Biosimilar Primer: US Physicians' Attitudes, Beliefs, and IntentionsResearch and Markets (http://www.researchandmarkets.com/research/n5nlsh/biosimilar) has announced the addition of the "Biosimilar Primer: US Physicians' Attitudes, Beliefs, and Intentions" report to their offering. This report features survey data portraying the perspectives of US physicians (cardiologists, CNS/ neurologists, oncologists, PCP, and respiratory/ pulmonologists) regarding their familiarity and prescription propensity for biosimilar products. In comparison to the 2013 Biosimilar Primer report, physician familiarity with biosimilars has increased. With this data, biopharmaceutica companies, payers, and service providers can make more informed decisions regarding product marketing, delivery, and manufacturing. What you will learn in this report: This report surveyed board certified cardiologists, CNS/ neurologists, oncologists, PCP, and respiratory/ pulmonologists in the US to gain insight into: - The level of familiarity physicians have with biosimilars - Intentions for prescribing based on biosimilar pricing - Opinions of pharmacy switching - Beliefs on the required clinical development process for biosimilar approval Report Structure: Executive summary Familiarity with biosimilars Prescribing and pricing - Medicine identification - Likelihood of prescribing a recently approved biosimilar - Discount required for physician recommendation Switching and DAW preference - Importance of being notified of pharmacy-level substitution - Opinion on EU ban on pharmacy-level substitution - Expected biologic prescriptions to be written with a DAW clause - Likelihood to use DAW clause - Preferred clinical testing for biosimilars For more information visit http://www.researchandmarkets.com/research/n5nlsh/biosimilar
|
